600195.SH
中牧股份
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 6.73
+0.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.5B | 6.2B | 6.0B | 5.4B | 5.9B |
| Cost of Revenue | 5.3B | 5.1B | 5.0B | 4.3B | 4.6B |
| Gross Profit | 1.1B | 1.1B | 984.3M | 1.1B | 1.3B |
| Operating Expenses | |||||
| R&D Expense | 160.5M | 152.8M | 143.9M | 122.8M | 143.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 329.1M | 343.3M | 326.1M | 322.7M | 339.2M |
| Selling & Marketing Expense | 514.4M | 498.4M | 440.3M | 362.2M | 378.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.1B | 968.6M | 854.5M | 889.7M |
| Cost and Expenses | 6.4B | 6.2B | 6.0B | 5.2B | 5.5B |
| Operating Income (EBIT) | 244.5M | 261.8M | 93.1M | 402.8M | 622.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 200.3M | 217.9M | 98.2M | 406.4M | 626.5M |
| Income Tax Expense | 52.8M | 41.6M | 36.8M | 59.4M | 76.0M |
| Bottom Line | |||||
| Net Income | 131.5M | 171.3M | 70.9M | 403.1M | 550.1M |
| Earnings from Cont. Ops | 147.6M | 176.2M | 61.4M | 346.9M | 550.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 131.5M | 171.3M | 70.9M | 403.1M | 550.1M |
| Per Share | |||||
| Basic EPS | CN¥0.13 | CN¥0.17 | CN¥0.07 | CN¥0.39 | CN¥0.54 |
| Diluted EPS | CN¥0.13 | CN¥0.17 | CN¥0.07 | CN¥0.39 | CN¥0.54 |
| Revenue Per Share | CN¥6.33 | CN¥6.08 | CN¥5.89 | CN¥5.29 | CN¥5.78 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Diluted Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | 608.1M | 413.2M | 699.2M | 890.0M |
| D&A | — | 346.3M | 320.1M | 296.4M | 267.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026